199 related articles for article (PubMed ID: 28611047)
21. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
22. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
23. The dynamics of DNA topoisomerase IIalpha in living cells.
Daum JR; Mo YY; Gorbsky GJ
Methods Mol Biol; 2009; 582():233-44. PubMed ID: 19763954
[TBL] [Abstract][Full Text] [Related]
24. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Mo YY; Beck WT
Exp Cell Res; 1999 Oct; 252(1):50-62. PubMed ID: 10502399
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Qi X; Hou S; Lepp A; Li R; Basir Z; Lou Z; Chen G
J Biol Chem; 2011 Oct; 286(41):35883-35890. PubMed ID: 21878638
[TBL] [Abstract][Full Text] [Related]
26. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
27. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress.
Shinagawa H; Miki Y; Yoshida K
Antioxid Redox Signal; 2008 May; 10(5):939-49. PubMed ID: 18162055
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
29. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase IIalpha controls the decatenation checkpoint.
Luo K; Yuan J; Chen J; Lou Z
Nat Cell Biol; 2009 Feb; 11(2):204-10. PubMed ID: 19098900
[TBL] [Abstract][Full Text] [Related]
31. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells.
Akimitsu N; Kamura K; Toné S; Sakaguchi A; Kikuchi A; Hamamoto H; Sekimizu K
Biochem Biophys Res Commun; 2003 Jul; 307(2):301-7. PubMed ID: 12859955
[TBL] [Abstract][Full Text] [Related]
33. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
34. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
35. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
36. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
[TBL] [Abstract][Full Text] [Related]
37. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
Salmena L; Lam V; McPherson JP; Goldenberg GJ
Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
[TBL] [Abstract][Full Text] [Related]
38. DNA topoisomerase IIα controls replication origin cluster licensing and firing time in Xenopus egg extracts.
Gaggioli V; Le Viet B; Germe T; Hyrien O
Nucleic Acids Res; 2013 Aug; 41(15):7313-31. PubMed ID: 23757188
[TBL] [Abstract][Full Text] [Related]
39. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
[TBL] [Abstract][Full Text] [Related]
40. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
